Evaluation of the Safety and Efficacy of Late-onset Pompe Disease Gene Therapy Drug

Key facts

Sponsor

GeneCradle Inc

Principal Investigator

Guang Yang

Chinese PLA General Hospital

Intervention

GC301(genetic)

Enrollment

33 enrolled

Eligibility

6 years · All sexes

Timeline

2024 – 2026

Study locations (1)

• Chinese PLA General Hospital, Beijing, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Glycogen storage disease due to acid maltase deficiency

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT07478172
  Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
  University of Missouri-Columbia
• RECRUITINGPHASE1, PHASE2NCT07282847
  A Study to Evaluate Safety, Tolerability, and Efficacy of AB-1009 Gene Therapy (GAA Gene) in Adult Participants With Late Onset Pompe Disease (PROGRESS-GT LOPD)
  AskBio Inc
• RECRUITINGPHASE2NCT07123155
  Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD)
  Shionogi
• RECRUITINGPHASE4NCT06666413
  China Post-approval Commitment (PAC) Study of Avalglucosidase Alfa in Participants With IOPD
  Genzyme, a Sanofi Company
• RECRUITINGNCT06795152
  Rare Glycogen Storage Diseases Natural History Study
  Duke University
• RECRUITINGNCT06121011
  A Global Prospective Observational Registry of Patients With Pompe Disease
  Amicus Therapeutics
• ACTIVE NOT RECRUITINGEARLY PHASE1NCT06109948
  Study to Assess the Safety, Tolerability, PK and PD of ABX1100
  Aro Biotherapeutics
• ACTIVE NOT RECRUITINGNCT05943678
  Novel Metabolic Muscular Biomarkers in Pompe Disease - a Non-invasive Magnetic Resonance Exploratory Pilot Study.
  Medical University of Vienna

See all trials for Glycogen storage disease due to acid maltase deficiency →